NMN

Nicotinamide mononucleotide (NMN) is a naturally occurring nucleotide derived from vitamin B3 (niacin) family compounds. It is the immediate biochemical precursor of nicotinamide adenine dinucleotide (NAD+), assembled into NAD+ in a single enzymatic step by nicotinamide mononucleotide adenylyltransferase (NMNAT). Oral NMN reliably raises blood NAD+ in human trials at doses from 150 mg to 1,250 mg per day. Functional clinical benefits in healthy adults remain modest and inconsistent.

NMN is found in food in small amounts: edamame, broccoli, cucumber, cabbage, and avocado contain trace quantities. The body also synthesizes it endogenously from nicotinamide riboside (NR) via nicotinamide riboside kinase. Molecular weight is 334.22 g/mol. The molecule consists of a nicotinamide base attached to a ribose 5-phosphate, structurally one step downstream of NR and one step upstream of NAD+ in the salvage biosynthesis pathway.

The Aging Hypothesis

The NMN longevity story traces to Shinichiro Imai's lab at Washington University in St. Louis. The 2016 mouse study by Mills, Yoshino, and Imai gave NMN to aged mice for 12 months and observed improvements in insulin sensitivity, energy expenditure, eye function, and physical activity compared with untreated controls. That preclinical signal launched the commercial NMN industry and made NMN a central compound in longevity-supplement marketing, particularly after David Sinclair publicly stated he takes NMN daily.

The Human Evidence

More than a dozen randomized controlled trials in humans have been published since 2020. They consistently show two things and inconsistently show a third.

Consistent finding 1: NMN raises blood NAD+. Irie et al., 2020 gave 100, 250, or 500 mg single doses to 10 healthy men and documented dose-dependent increases in plasma NMN and downstream metabolites.

Consistent finding 2: NMN is well-tolerated. The Song et al. 2023 review in Advances in Nutrition aggregated safety data across published human trials and concluded that NMN supplementation has not produced characteristic safety signals.

Inconsistent finding: functional benefits. The most-cited efficacy study is Yoshino et al., Science 2021, in which 25 prediabetic postmenopausal women received 250 mg NMN per day for 10 weeks and showed improved muscle insulin sensitivity compared with 25 placebo controls. The effect was modest, the cohort was specific, and the trial was small.

The Liao et al. 2021 trial in 48 amateur runners reported dose-dependent improvements in aerobic capacity (VO2max) at 300, 600, and 1,200 mg per day over 6 weeks. The Wen et al. 2024 systematic review of 10 RCTs (437 patients, mean age 58, 4-12 weeks of treatment) concluded that NMN showed signals for improved physical performance with minimal complications.

The Pham et al. meta-analysis on glucose and lipid metabolism reviewed 8 RCTs (342 adults, 250-2,000 mg per day, 14 days to 12 weeks). It found no significant benefit on fasting glucose, fasting insulin, HbA1c, HOMA-IR, or lipid profile.

The pattern across this body of work: biomarker effects are real and reproducible. Whole-organism functional effects are modest at best, and depend heavily on the cohort selected.

Regulatory and Legal Status

The three-year US regulatory saga:

May 2022: Chinese firm SyncoZymes received the first FDA acknowledgment of an NDI (New Dietary Ingredient) notification for NMN, with the agency agreeing that NMN met the definition of a dietary ingredient and that the safety case was adequate.

October 2022: Inner Mongolia Kingdomway Pharmaceutical submitted a similar NDI notification.

November 2022: The FDA reversed position. The agency stated that NMN was excluded from the dietary supplement definition because Metro International Biotech, Inc. had authorized NMN for investigation as a new drug, and substantial clinical investigations were underway, before NMN was lawfully marketed as a supplement. This triggered the "drug preclusion" clause of the Dietary Supplement Health and Education Act (DSHEA).

2022-2025: NMN sales continued in the US despite the FDA position, with patchy retailer enforcement. Amazon delisted some products. Direct-to-consumer brands continued selling.

August 2024: The Natural Products Association (NPA) filed a citizen petition and a federal lawsuit against the FDA in Washington, DC.

September 29, 2025: The FDA issued two letters reversing its position. The agency acknowledged evidence that NMN had been marketed as a dietary supplement in the US as early as 2017, predating the IND authorization. Under the "race to market" provision, this meant NMN qualified as a dietary supplement. The agency confirmed that NMN is not excluded from the definition.

Outside the US: NMN is sold as a dietary supplement or food ingredient in Japan (origin market for many trials), most of Asia, and Australia. In the European Union, NMN's status as a novel food is unresolved. The European Food Safety Authority has not issued a definitive opinion. Several EU countries treat it as an unauthorized novel food and have restricted commercial sale.

NMN is not on the WADA Prohibited List. Use in competitive sport is permitted.

NMN feeds the NAD+ salvage pathway, the dominant NAD+ biosynthesis route in most human tissues. The pathway runs as follows:

Nicotinamide → (NAMPT) → NMN → (NMNAT1/2/3) → NAD+

NMNAT1 operates in the nucleus, NMNAT2 in the cytosol and Golgi, NMNAT3 in mitochondria. Each adds an AMP group from ATP to NMN to produce NAD+. Adding exogenous NMN bypasses the NAMPT step, which is the rate-limiting enzyme in salvage and is downregulated in aged tissues. This is the mechanistic argument for NMN supplementation.

The cellular uptake of NMN is the contested part of the story. NMN is phosphorylated and charged, and the prevailing view through 2018 was that it could not directly cross cell membranes. Cells were thought to dephosphorylate extracellular NMN to NR via CD73 ectonucleotidase, take up the NR through equilibrative nucleoside transporters (ENT1/2), and then re-phosphorylate NR to NMN intracellularly using nicotinamide riboside kinase. This routing makes NMN supplementation functionally equivalent to NR supplementation, with an extra step.

Yoshida et al. (2019) proposed an alternative: a direct NMN transporter, SLC12A8, expressed at high levels in the small intestine. Subsequent independent attempts to replicate the SLC12A8 finding have produced conflicting results. The mainstream view is that direct NMN uptake exists but is tissue-limited and quantitatively modest compared with the indirect NR-mediated route.

Pharmacokinetics: Oral NMN reaches peak plasma concentration within 30 minutes. Plasma half-life is approximately 1-2 hours, with the molecule rapidly converted to downstream metabolites. Steady-state increases in blood NAD+ are typically observed within 1-2 weeks of consistent dosing.

The downstream consequences of elevated NAD+ are the same as discussed for NAD+: increased substrate availability for sirtuins, PARPs, and CD38, and potential changes in mitochondrial biogenesis, DNA repair efficiency, and oxidative stress response.

The reproducible effect of NMN in human trials is elevation of blood NAD+ and related metabolites. This is documented at virtually every dose tested.

Functional effects reported across trials include:

• Aerobic capacity in amateur runners: Liao 2021, 6 weeks at 300-1,200 mg/day, dose-dependent VO2max improvement.
• Muscle insulin sensitivity in prediabetic postmenopausal women: Yoshino 2021, 10 weeks at 250 mg/day, modest improvement.
• Physical performance in older adults: Igarashi et al. 2022, 12 weeks at 250 mg/day in men over 65, improvements in muscle strength and walking distance.
• Skeletal muscle insulin signaling: Yi et al. 2023, 60 days at 300-900 mg/day, improvements in walking and biological aging markers.
• Sleep quality and fatigue: smaller trials report subjective improvements. Data is preliminary.

Effects that have NOT consistently been demonstrated include:

• Fasting glucose, HbA1c, or lipid profile in non-diabetic adults (Pham meta-analysis found no significant change)
• Maximal aerobic capacity in elite athletes (the available data is in amateurs, not athletes near their physiological ceiling)
• Cognitive function in healthy adults (animal data is positive, human data is sparse)
• Lifespan or all-cause mortality (no human study has tested this)

The translation gap between rodent and human studies is significant. Mouse trials report large effects on muscle function, vascular function, and survival. Human trials report consistent NAD+ elevation but modest, cohort-dependent functional changes.

Published trial doses range from 150 mg to 1,250 mg per day, taken orally, typically once daily in the morning.

Specific dose-finding studies:

• The Irie 2020 single-dose pharmacokinetic trial tested 100, 250, and 500 mg in 10 healthy men. All doses raised plasma NMN. The 500 mg dose produced the largest NAD+ elevation.
• The Yoshino 2021 Science trial used 250 mg per day for 10 weeks.
• The Liao 2021 amateur runner trial tested 300, 600, and 1,200 mg per day over 6 weeks, with dose-dependent VO2max increases.
• The Christen 2026 head-to-head trial used 1,000 mg per day for 14 days against NR and nicotinamide.
• The Yamamoto 2024 safety study used 1,250 mg per day for 4 weeks.

The commercial market typically sells NMN in 125, 250, 300, or 500 mg capsules. Many users take one or two capsules in the morning. Sublingual NMN powder is also sold, with the claim that buccal absorption bypasses gut conversion to NR. Supporting human pharmacokinetic data is sparse.

Timing: most trials dose NMN once daily in the morning. The rationale is alignment with circadian NAD+ pulse, which peaks in the morning. Splitting the dose has not been formally compared.

Cycling: there is no controlled human trial of NMN cycling protocols. Continuous daily dosing for 4-24 weeks is the dominant trial design.

The Sinclair protocol, as publicly described by David Sinclair, uses 1 g per day of NMN in the morning, taken with TMG (trimethylglycine, 500-1,000 mg) to offset methyl donor depletion. This is not a controlled-trial-validated protocol. It is a personal regimen widely publicized.

No standardized human dosing protocol exists for NMN beyond the safety-tested ranges in published trials. The mechanism of action is sufficiently characterized that mg-level doses are clearly in the active range, but the optimal dose for any specific functional endpoint in any specific population has not been established.

NMN is among the best-tolerated longevity interventions in clinical trial data. Across the published human trials reviewed by Song 2023 and Wen 2024, the most commonly reported adverse effects are mild and gastrointestinal: nausea, abdominal discomfort, occasional diarrhea, particularly at doses above 1,000 mg per day.

A small subset of users report mild flushing, similar to but milder than the flushing associated with high-dose nicotinic acid (niacin). The mechanism is prostaglandin-mediated and is dose-dependent.

Theoretical concerns at chronic high doses:

• Methyl donor depletion: NAD+ metabolism consumes methyl groups via nicotinamide N-methyltransferase (NNMT), converting nicotinamide to N-methyl-nicotinamide using S-adenosyl-methionine (SAM). Sustained high-dose NMN may deplete SAM. The practical recommendation circulating is to co-supplement with 500-1,000 mg TMG daily. Empirical evidence for this is limited.
• Cancer biology: NAD+ supports proliferation of dividing cells. The implications for occult or active cancers are unresolved. NMN supplementation is not recommended during active cancer treatment without oncologist input.
• Long-term effects: the longest published human NMN trials are approximately one year. Effects of multi-year continuous supplementation are not characterized.
• CD38 and immune effects: chronic NAD+ elevation may affect CD38-mediated immune signaling. The clinical significance is unknown.

Quality control of commercial product is the practical safety issue most often overlooked. NMN is unstable in some conditions, and degradation to nicotinamide during storage or manufacturing is reported. Independent third-party testing of commercial NMN products has documented batch-to-batch variation and occasional contamination with degradation products. Third-party tested products are preferable.

Drug interactions are not well-characterized at NMN supplement doses. PARP inhibitors (olaparib, rucaparib, niraparib, talazoparib) used in some cancer regimens block NAD+ consumers, and co-supplementing the substrate is a poorly characterized interaction.

NMN is the central compound in the longevity-supplement stack ecosystem. Common pairings:

The pairing with NR (nicotinamide riboside) is mechanistically redundant: both feed the salvage pathway. The Christen 2026 head-to-head found them equivalent for raising NAD+. Combining them does not appear to produce additive effects in available data.

The pairing with TMG (trimethylglycine, betaine) is the most-discussed addition. The rationale is offsetting methyl donor consumption at high NMN doses. Sinclair has publicly stated he takes TMG with NMN. Empirical evidence for the benefit is mechanistic rather than trial-confirmed.

The pairing with resveratrol is the original Sinclair-protocol stack. Resveratrol activates SIRT1. NMN provides the NAD+ substrate that SIRT1 requires. Whether the combination outperforms either alone in humans is not established by controlled trial.

The pairing with SS-31 addresses mitochondrial redox at a different layer: SS-31 stabilizes cardiolipin, NMN provides salvage-pathway substrate. Mechanistically complementary, clinically untested as a combination.

The pairing with methylene blue is mechanistically complementary: methylene blue cycles electrons past damaged ETC complexes, while NMN supplies the substrate for those electrons via NAD+. The combination is widely discussed in biohacking circles. Controlled human data does not exist.

The pairing NMN should be approached carefully with is PARP inhibitors in oncology regimens. PARP inhibitors block one of the major NAD+ consumers. Supplementing the substrate creates a poorly characterized interaction.

For informational and educational purposes only. Not medical advice. Not for human consumption unless prescribed by a licensed physician for an FDA-approved indication. Consult a qualified healthcare provider before using any peptide or pharmaceutical product.